A double blind, randomised, dose finding, phase II, multicentre study of radium-223 for the treatment of patients with metastatic castration-refractory prostate cancer (CRPC): EudraCT number: 2005-003680-22

Autoria(s): Parker, C.; Hoskin, R.; Pascoe, S.; Chodack, A.; O'Sullivan, Joe; Germa, J.R.; Lokna, A.
Data(s)

01/09/2009
Identificador

http://pure.qub.ac.uk/portal/en/publications/a-double-blind-randomised-dose-finding-phase-ii-multicentre-study-of-radium223-for-the-treatment-of-patients-with-metastatic-castrationrefractory-prostate-cancer-crpc-eudract-number-200500368022(5084578e-67c8-41c6-a679-253433d9cfbc).html
Idioma(s)

eng
Direitos

info:eu-repo/semantics/restrictedAccess
Fonte

Parker , C , Hoskin , R , Pascoe , S , Chodack , A , O'Sullivan , J , Germa , J R & Lokna , A 2009 , ' A double blind, randomised, dose finding, phase II, multicentre study of radium-223 for the treatment of patients with metastatic castration-refractory prostate cancer (CRPC): EudraCT number: 2005-003680-22 ' EJC SUPPLEMENTS , vol 7 , pp. 406-406 .
Tipo

article
Acesso ao item digital